Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects.
Geelen IGP, Gullaksen SE, Ilander MM, Olssen-Strömberg U, Mustjoki S, Richter J, Blijlevens NMA, Smit WM, Gjertsen BT, Gedde-Dahl T, Markevärn B, Koppes MMA, Westerweel PE, Hjorth-Hansen H, Janssen JJWM. Geelen IGP, et al. Among authors: ilander mm. Ann Hematol. 2023 Jun;102(6):1395-1408. doi: 10.1007/s00277-023-05199-1. Epub 2023 Apr 29. Ann Hematol. 2023. PMID: 37119314 Clinical Trial.
Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.
Ilander M, Olsson-Strömberg U, Schlums H, Guilhot J, Brück O, Lähteenmäki H, Kasanen T, Koskenvesa P, Söderlund S, Höglund M, Markevärn B, Själander A, Lotfi K, Dreimane A, Lübking A, Holm E, Björeman M, Lehmann S, Stenke L, Ohm L, Gedde-Dahl T, Majeed W, Ehrencrona H, Koskela S, Saussele S, Mahon FX, Porkka K, Hjorth-Hansen H, Bryceson YT, Richter J, Mustjoki S. Ilander M, et al. Leukemia. 2017 May;31(5):1108-1116. doi: 10.1038/leu.2016.360. Epub 2016 Nov 28. Leukemia. 2017. PMID: 27890936 Free PMC article. Clinical Trial.
Immune control in chronic myeloid leukemia.
Ilander M, Mustjoki S. Ilander M, et al. Oncotarget. 2017 Nov 3;8(61):102763-102764. doi: 10.18632/oncotarget.22279. eCollection 2017 Nov 28. Oncotarget. 2017. PMID: 29262520 Free PMC article. No abstract available.
Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival.
Brück O, Dufva O, Hohtari H, Blom S, Turkki R, Ilander M, Kovanen P, Pallaud C, Ramos PM, Lähteenmäki H, Välimäki K, El Missiry M, Ribeiro A, Kallioniemi O, Porkka K, Pellinen T, Mustjoki S. Brück O, et al. Blood Adv. 2020 Jan 28;4(2):274-286. doi: 10.1182/bloodadvances.2019000792. Blood Adv. 2020. PMID: 31968078 Free PMC article.
25 results